

***Fiscal Year 2024 Department of Defense Tuberos Sclerosis Complex Research Program (TSCRCP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Exploration – Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524TSCRPEHDA</p>	<p>Investigators at or above postdoctoral fellow (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the tuberous sclerosis complex (TSC) research field. • Projects involving human subjects or human biological substances must be exempt under Title 32 of the Code of Regulations, Part 219.104(d) (32 CFR 219.104(d)), or be eligible for expedited review under 21 CFR 56.110. • Research projects must be innovative, feasible and supported by a strong rationale. • Innovation is an important review criterion. • <i>Preliminary data allowed but not required.</i> • <i>Clinical trials not allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$150,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): June 12, 2024 5:00 p.m. Eastern time</p> <p>Application: August 1, 2024 11:59 p.m. Eastern time</p>
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524TSCRPIDA</p>	<p><i>Established Investigator:</i></p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p> <p><i>or</i></p> <p><i>New-to-the-Field Investigator:</i></p> <p>Independent investigators at or below the level of Assistant Professor (or equivalent) or established independent investigators in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC, thereby bringing their expertise to the field.</p>	<ul style="list-style-type: none"> • Supports new ideas that have the potential to yield high-impact findings and new avenues of investigation. • Impact and Innovation are important review criteria. • <i>Preliminary data are expected.</i> • <i>Clinical trials not allowed.</i> • <i>New-to-the-Field Investigators Option</i> supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in the field of TSC research. • Applications from New-to-the-Field Investigators and Established Investigators will be peer and programmatically reviewed separately. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$500,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): June 12, 2024 5:00 p.m. Eastern time</p> <p>Application: August 1, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524TSCRPCTRA</p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including the diagnosis, prognosis or treatment of TSC. • Applications may include correlative studies that are associated with a completed clinical trial. • Studies advancing clinical trial readiness through the development of biomarkers, clinical endpoints and validation of pharmacokinetic/pharmacodynamics, as well as studies piloting clinical trials that include behavioral interventions, are of particular interest. • Applications may include a small pilot clinical trial intended to inform the next step in the continuum of translational research. • Supports studies that encompass the analysis of existing real-world data practices to develop/improve guidelines for better outcomes in defined areas relevant to the focus areas of the program. • Preclinical studies may be appropriate, but must include a clinical component. • Projects that are exploratory and/or strictly animal research will not be considered for funding. • Clinical Translational Potential and Impact are important review criteria. • Partnering PI Option available. • Collaborations between laboratory scientists and clinicians are strongly encouraged. • Preliminary data required. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,000,000 for direct costs. • The maximum allowable funding for the entire period of performance is \$1,150,000 for direct costs for applications including a Partnering PI Option. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): June 12, 2024 5:00 p.m. Eastern time</p> <p>Application: August 1, 2024 11:59 p.m. Eastern time</p>